Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2016

View Archived Issues

Amgen and Advaxis enter global collaboration to develop cancer immunotherapies

Catalent Biologics and Zumutor work together to create antibodies with enhanced ADCC activity

CYC-065 as a promising new therapy option for resistant/recurrent uterine serous carcinoma

Genetic variation in COMT modifies effects of clonidine treatment

Novel bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer

Merck & Co. develops factor XIa inhibitors

Boehringer Ingelheim Pharma patents AMPK activators

Vivreon Biosciences announces calcium activated channel modulators

Daiichi Sankyo discloses RORgammat antagonists

Inovio continues to independently develop INO-1800 for the treatment of hepatitis B

Cellectar Biosciences receives second phase of NCI contract award

Philogen, Janssen Biotech to collaborate on immunomodulatory therapeutics

Takeda presents milestones of first quarter of fiscal 2016

Sanofi reflects on accomplishments of first quarter 2016

AstraZeneca offers overview of developments in second quarter 2016

FibroStatin reports promising preclinical results on T-12

Editas Medicine obtains license to genome-editing technology

Amicus Therapeutics to submit NDA in Japan for migalastat next year

Myriad Genetics to acquire Assurex Health

Santen to collaborate with University College London on ophthalmic research and education

Sorrento Therapeutics and CHA biotech to form joint venture

Meiji Seika Pharma outlicenses MS drug candidate to new company

FDA places partial clinical hold on planned NY-ESO SPEAR T-cell therapy study

Milestone reached in Evotec, Bayer endometriosis collaboration

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...